NCT00038571View on ClinicalTrials.gov

Proteasome Inhibitor PS-341 Relapsed or Refractory B Cell Lymphomas Previously Treated With Chemotherapy

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 31, 2002

Primary Completion Date

March 31, 2005

Study Completion Date

March 31, 2005

Conditions
Lymphoma, B-Cell
Interventions
DRUG

PS341 (Bortezomib)

1.5 mg/m2 intravenous (IV) bolus push over 3 to 5 seconds on days 1, 4, 8, and 11, followed by a 10-day rest for a 21-day cycle.

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER